United Therapeutics (UTHR) reported Q1 earnings Wednesday of $5.82 per diluted share, down from $6.63 a year earlier.
Analysts polled by FactSet expected $7.
Revenue for the quarter ended March 31 was $781.5 million, compared with $794.4 million a year earlier.
Analysts polled by FactSet expected $797.4 million.